Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
1.
Clin Infect Dis ; 55(10): 1320-8, 2012 Nov 15.
Article in English | MEDLINE | ID: mdl-22828595

ABSTRACT

BACKGROUND: The Shingles Prevention Study (SPS; Department of Veterans Affairs Cooperative Study 403) demonstrated that zoster vaccine was efficacious through 4 years after vaccination. The Short-Term Persistence Substudy (STPS) was initiated after the SPS to further assess the persistence of vaccine efficacy. METHODS: The STPS re-enrolled 7320 vaccine and 6950 placebo recipients from the 38 546-subject SPS population. Methods of surveillance, case determination, and follow-up were analogous to those in the SPS. Vaccine efficacy for herpes zoster (HZ) burden of illness, incidence of postherpetic neuralgia (PHN), and incidence of HZ were assessed for the STPS population, for the combined SPS and STPS populations, and for each year through year 7 after vaccination. RESULTS: In the STPS as compared to the SPS, vaccine efficacy for HZ burden of illness decreased from 61.1% to 50.1%, vaccine efficacy for the incidence of PHN decreased from 66.5% to 60.1%, and vaccine efficacy for the incidence of HZ decreased from 51.3% to 39.6%, although the differences were not statistically significant. Analysis of vaccine efficacy in each year after vaccination for all 3 outcomes showed a decrease in vaccine efficacy after year 1, with a further decline thereafter. Vaccine efficacy was statistically significant for the incidence of HZ and the HZ burden of illness through year 5. CONCLUSIONS: Vaccine efficacy for each study outcome was lower in the STPS than in the SPS. There is evidence of the persistence of vaccine efficacy through year 5 after vaccination but, vaccine efficacy is uncertain beyond that point.


Subject(s)
Herpes Zoster Vaccine/administration & dosage , Herpes Zoster/prevention & control , Aged , Cohort Studies , Cost of Illness , Double-Blind Method , Epidemiological Monitoring , Herpes Zoster/epidemiology , Herpes Zoster/immunology , Herpes Zoster Vaccine/immunology , Humans , Incidence , Middle Aged , Placebos , United States/epidemiology , Vaccination/statistics & numerical data
2.
N Engl J Med ; 352(22): 2271-84, 2005 Jun 02.
Article in English | MEDLINE | ID: mdl-15930418

ABSTRACT

BACKGROUND: The incidence and severity of herpes zoster and postherpetic neuralgia increase with age in association with a progressive decline in cell-mediated immunity to varicella-zoster virus (VZV). We tested the hypothesis that vaccination against VZV would decrease the incidence, severity, or both of herpes zoster and postherpetic neuralgia among older adults. METHODS: We enrolled 38,546 adults 60 years of age or older in a randomized, double-blind, placebo-controlled trial of an investigational live attenuated Oka/Merck VZV vaccine ("zoster vaccine"). Herpes zoster was diagnosed according to clinical and laboratory criteria. The pain and discomfort associated with herpes zoster were measured repeatedly for six months. The primary end point was the burden of illness due to herpes zoster, a measure affected by the incidence, severity, and duration of the associated pain and discomfort. The secondary end point was the incidence of postherpetic neuralgia. RESULTS: More than 95 percent of the subjects continued in the study to its completion, with a median of 3.12 years of surveillance for herpes zoster. A total of 957 confirmed cases of herpes zoster (315 among vaccine recipients and 642 among placebo recipients) and 107 cases of postherpetic neuralgia (27 among vaccine recipients and 80 among placebo recipients) were included in the efficacy analysis. The use of the zoster vaccine reduced the burden of illness due to herpes zoster by 61.1 percent (P<0.001), reduced the incidence of postherpetic neuralgia by 66.5 percent (P<0.001), and reduced the incidence of herpes zoster by 51.3 percent (P<0.001). Reactions at the injection site were more frequent among vaccine recipients but were generally mild. CONCLUSIONS: The zoster vaccine markedly reduced morbidity from herpes zoster and postherpetic neuralgia among older adults.


Subject(s)
Chickenpox Vaccine , Herpes Zoster/prevention & control , Herpesvirus 3, Human , Neuralgia/prevention & control , Aged , Chickenpox Vaccine/adverse effects , Chickenpox Vaccine/immunology , Cost of Illness , Double-Blind Method , Female , Follow-Up Studies , Herpes Zoster/complications , Herpes Zoster/epidemiology , Herpesvirus 3, Human/immunology , Humans , Immunologic Memory , Incidence , Male , Middle Aged , Neuralgia/virology , Vaccines, Attenuated/adverse effects , Vaccines, Attenuated/immunology , Virus Activation
3.
Arch Virol Suppl ; (17): 135-42, 2001.
Article in English | MEDLINE | ID: mdl-11339542

ABSTRACT

The limited supple of appropriate tissues for study has been an impediment to investigations of varicella zoster virus (VZV) latency. Human dorsal root ganglia (DRG) harboring latent virus are not plentiful and are not amenable to manipulation for studying the events surrounding the establishment, maintenance, and cessation of latency. An alternative to studies in human DRG is the rat model of latency, which appears to provide a reliable method of investigating VZV latency. Other alternatives include studies in other human tissues involved in VZV pathogenesis. In order to improve our understanding of the establishment and cessation of latency, we performed comparative immunohistochemical analysis of chickenpox and zoster skin lesions. This analysis revealed that during primary infection and reactivation productive VZV infection occurs in a variety of cell types and that the major VZV DNA binding protein, ORF29p, is present in peripheral axons early during the course of chickenpox. VZV latency was studied in the rat model by in situ hybridization and compared with similar studies performed in human DRG containing latent virus, confirming that VZV DNA persists in the same sites in DRG of the two species.


Subject(s)
Chickenpox/virology , Herpes Zoster/virology , Virus Activation , Virus Latency , Animals , Chickenpox/metabolism , Chickenpox/pathology , Ganglia, Spinal/pathology , Ganglia, Spinal/virology , Herpes Zoster/metabolism , Herpes Zoster/pathology , Herpesvirus 3, Human/growth & development , Herpesvirus 3, Human/isolation & purification , Herpesvirus 3, Human/metabolism , Herpesvirus 3, Human/physiology , Humans , Rats , Skin/pathology , Skin/virology
4.
J Virol ; 74(23): 11311-21, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11070031

ABSTRACT

We report the discovery of a novel gene in the varicella-zoster virus (VZV) genome, designated open reading frame (ORF) S/L. This gene, located at the left end of the prototype VZV genome isomer, expresses a polyadenylated mRNA containing a splice within the 3' untranslated region in virus-infected cells. Sequence analysis reveals significant differences between the ORF S/Ls of wild-type and attenuated strains of VZV. Antisera raised to a bacterially expressed portion of ORF S/L reacted specifically with a 21-kDa protein synthesized in cells infected with a VZV clinical isolate and with the original vaccine strain of VZV (Oka-ATCC). Cells infected with other VZV strains, including a wild-type strain that has been extensively passaged in tissue culture and commercially produced vaccine strains of Oka, synthesize a family of proteins ranging in size from 21 to 30 kDa that react with the anti-ORF S/L antiserum. MeWO cells infected with recombinant VZV harboring mutations in the C-terminal region of the ORF S/L gene lost adherence to the stratum and adjacent cells, resulting in an altered plaque morphology. Immunohistochemical analysis of VZV-infected cells demonstrated that ORF S/L protein localizes to the cytoplasm. ORF S/L protein was present in skin lesions of individuals with primary or reactivated infection and in the neurons of a dorsal root ganglion during virus reactivation.


Subject(s)
Cytoplasm/chemistry , Genome, Viral , Herpesvirus 3, Human/genetics , Open Reading Frames , Viral Proteins/genetics , Adult , Amino Acid Sequence , Animals , Base Sequence , Chlorocebus aethiops , Ganglia, Spinal/chemistry , Humans , Molecular Sequence Data , Mutation , RNA, Viral/chemistry , Rabbits , Recombination, Genetic , Skin/chemistry , Vero Cells , Viral Proteins/analysis
5.
J Virol ; 74(4): 2005-10, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10644373

ABSTRACT

Skin biopsy samples from varicella-zoster virus (VZV)-infected patients examined by immunohistochemistry demonstrated VZV replication in nonepithelial cell types. ORF29p, a nonstructural nuclear protein, was found in nerves of two of six patients with chickenpox. In tissue culture, ORF29p was secreted by VZV-infected fibroblasts. Extracellular ORF29p can be taken up through endocytosis by human neurons, implying a novel role for this protein in pathogenesis.


Subject(s)
DNA-Binding Proteins/physiology , Herpesvirus 3, Human , Viral Nonstructural Proteins/physiology , Cells, Cultured , Chickenpox/pathology , Chickenpox/virology , DNA-Binding Proteins/metabolism , Endocytosis , Fibroblasts/cytology , Fibroblasts/metabolism , Fibroblasts/virology , Herpes Zoster/pathology , Herpes Zoster/virology , Herpesvirus 3, Human/pathogenicity , Humans , Immunohistochemistry , Neurons/virology , Skin/pathology , Skin/virology , Viral Nonstructural Proteins/metabolism
7.
J Infect Dis ; 178 Suppl 1: S48-51, 1998 Nov.
Article in English | MEDLINE | ID: mdl-9852973

ABSTRACT

Latent varicella-zoster virus (VZV) was studied in ganglia of rats that had been inoculated subcutaneously with either a high-passaged wild-type, a low-passaged wild-type, or the vaccine strain of virus using in situ hybridization. Nine of 11 rats injected with virus and no control rats developed serum VZV antibodies as demonstrated by fluorescent antibody membrane antigen. Polymerase chain reaction 2 weeks following inoculation did not detect viremia in the rats. VZV was detected by in situ hybridization in ganglia of 10 of the 11 infected rats but not in ganglia of the control rats. The distribution of VZV DNA is identical to that seen in humans; satellite cells and neurons contain VZV DNA. Although all animals received unilateral injections of virus, VZV DNA was in ipsilateral and contralateral ganglia in 6 animals, suggesting that virus replication and viremia had occurred.


Subject(s)
Ganglia, Spinal/virology , Herpesvirus 3, Human/pathogenicity , Animals , Antibodies, Viral/blood , Chickenpox/immunology , Chickenpox/virology , Chickenpox Vaccine/immunology , DNA, Viral/genetics , DNA, Viral/isolation & purification , Herpes Zoster/immunology , Herpes Zoster/virology , Herpesvirus 3, Human/genetics , Herpesvirus 3, Human/immunology , Humans , In Situ Hybridization , Rats , Rats, Wistar , Species Specificity , Virus Activation , Virus Integration
8.
J Infect Dis ; 178(2): 539-43, 1998 Aug.
Article in English | MEDLINE | ID: mdl-9697739

ABSTRACT

Congenital varicella syndrome is a rare complication of varicella-zoster virus (VZV) infection during pregnancy. An infant was exposed to VZV at 18.5 weeks of gestation and had eye and skin abnormalities at birth and persistent feeding difficulties, prompting esophageal biopsies at 12 days and 20 and 20.5 months of age. Esophageal tissues demonstrated specialized intestinal metaplasia (Barrett's esophagus). VZV DNA (in situ hybridization) and proteins (immunohistochemistry and polymerase chain reaction) were found in esophageal epithelial cells adjacent to the Barrett's lesion. Immediate-early 63 protein (IE63) of VZV was demonstrated in the day 12 specimen, and IE62 and the late VZV glycoprotein E (gE) were found in the 20-month specimen. Clinical and endoscopic improvement followed fundoplication and acyclovir therapy, but VZV DNA and IE62 persisted in esophageal tissue. These findings associate VZV with specialized intestinal metaplasia within the esophagus and suggest a novel site for either latent or active VZV infection.


Subject(s)
Barrett Esophagus/virology , Esophagus/virology , Herpes Zoster/congenital , Pregnancy Complications, Infectious/virology , Barrett Esophagus/pathology , Barrett Esophagus/physiopathology , DNA, Viral/analysis , Esophagus/pathology , Female , Herpes Zoster/physiopathology , Herpes Zoster/virology , Humans , Immediate-Early Proteins/genetics , Infant , Infant, Newborn , Pregnancy , Pregnancy Complications, Infectious/pathology , Pregnancy Complications, Infectious/physiopathology , Trans-Activators/genetics , Viral Envelope Proteins/genetics , Virus Latency
9.
Proc Natl Acad Sci U S A ; 95(12): 7080-5, 1998 Jun 09.
Article in English | MEDLINE | ID: mdl-9618542

ABSTRACT

Varicella-Zoster virus (VZV) is a herpesvirus that becomes latent in sensory neurons after primary infection (chickenpox) and subsequently may reactivate to cause zoster. The mechanism by which this virus maintains latency, and the factors involved, are poorly understood. Here we demonstrate, by immunohistochemical analysis of ganglia obtained at autopsy from seropositive patients without clinical symptoms of VZV infection that viral regulatory proteins are present in latently infected neurons. These proteins, which localize to the nucleus of cells during lytic infection, predominantly are detected in the cytoplasm of latently infected neurons. The restriction of regulatory proteins from the nucleus of latently infected neurons might interrupt the cascade of virus gene expression that leads to a productive infection. Our findings raise the possibility that VZV has developed a novel mechanism for maintenance of latency that contrasts with the transcriptional repression that is associated with latency of herpes simplex virus, the prototypic alpha herpesvirus.


Subject(s)
Chickenpox/virology , Ganglia/virology , Herpesvirus 3, Human/physiology , Immediate-Early Proteins/physiology , Viral Proteins/physiology , Virus Latency/physiology , Aged , Aged, 80 and over , Humans , Male
11.
Clin Diagn Virol ; 7(2): 69-76, 1996 Nov.
Article in English | MEDLINE | ID: mdl-9137862

ABSTRACT

BACKGROUND: When virologic and molecular diagnostic techniques are unavailable, the diagnosis of varicella zoster virus (VZV) infection depends on clinical criteria and histologic evaluation of skin biopsy specimens or Tzank preparations. These methods can misdiagnose chickenpox and zoster, particularly when the clinical manifestations are atypical. OBJECTIVE: To improve diagnosis in these settings, we developed an in situ hybridization technique for the detection of VZV utilizing a fluorescein-labeled oligonucleotide probe visualized with anti-fluorescein alkaline phosphatase-conjugated antibody. STUDY DESIGN: We retrospectively examined 26 paraffin-embedded skin biopsy specimens with histologic features consistent with VZV or herpes simplex virus (HSV) infection and 11 control cases by in situ hybridization. In situ hybridization for VZV and HSV-1 was compared with polymerase chain reaction (PCR) for VZV and HSV-1 and clinical and histologic examination. RESULTS: Thirteen of the 26 study cases and two of the 11 control cases were positive for VZV by in situ hybridization. When compared with PCR, in situ hybridization was 92% sensitive and 88% specific. When compared with clinical diagnosis, in situ hybridization was 86% sensitive and 87% specific. All cases of chickenpox had VZV-positive inflammatory cells in the dermis but this finding was less frequent among the cases of zoster. CONCLUSIONS: This in situ hybridization technique is a sensitive and specific method for the diagnosis of VZV in skin lesions that is applicable to most histopathology laboratory settings. In addition, in situ hybridization reveals individual infected cells and may provide insight into the pathogenesis of VZV skin infection.


Subject(s)
Herpesvirus 3, Human/isolation & purification , In Situ Hybridization, Fluorescence , Skin/virology , Chickenpox/pathology , Chickenpox/virology , DNA, Viral/analysis , Herpes Zoster/pathology , Herpes Zoster/virology , Herpesvirus 1, Human/genetics , Herpesvirus 1, Human/isolation & purification , Herpesvirus 3, Human/genetics , Humans , Paraffin Embedding , Polymerase Chain Reaction , Retrospective Studies , Sensitivity and Specificity , Skin/pathology
12.
Proc Natl Acad Sci U S A ; 92(24): 10980-4, 1995 Nov 21.
Article in English | MEDLINE | ID: mdl-7479921

ABSTRACT

Ganglia obtained at autopsy were examined by in situ hybridization from one patient with zoster (also called herpes zoster or shingles), two varicella-zoster virus (VZV)-seropositive patients with clinical evidence of zoster, one VZV-seronegative child, and one fetus. Ganglia positive for VZV had a hybridization signal in both neuronal and nonneuronal satellite cells. Ganglia obtained from the fetus and from the seronegative infant were consistently negative for VZV. Two striking observations were evident regarding the presence of VZV DNA in ganglia obtained from the individual with zoster at the time of death. First, ganglia innervating the sites of reactivation and ganglia innervating adjacent sites yielded strongly positive signals in neurons and satellite cells, whereas ganglia from distant sites were rarely positive. Second, VZV DNA was found in both the nuclei and the cytoplasm of neurons innervating areas of zoster. However, in neurons innervating zoster-free areas, VZV DNA was found only in the nucleus of neurons and their supporting satellite cells. Immunohistochemistry with a fluorescent monoclonal antibody to the VZV glycoprotein gpI, a late virus protein, revealed a positive signal in the cytoplasm of ganglia with clinical evidence of reactivation. These results illustrate that both neuronal and satellite cells become latently infected following primary VZV infection. The presence of VZV DNA and gpI in the cytoplasm of neurons demonstrates productive infection following reactivation at the site of latency.


Subject(s)
Ganglia, Spinal/microbiology , Herpes Zoster/microbiology , Herpesvirus 3, Human/growth & development , Virus Latency , Antigens, Viral/metabolism , Base Sequence , DNA Primers/chemistry , DNA, Viral/analysis , Humans , In Situ Hybridization , Molecular Sequence Data , Viral Envelope Proteins/metabolism
13.
J Bacteriol ; 177(2): 312-9, 1995 Jan.
Article in English | MEDLINE | ID: mdl-7814319

ABSTRACT

The K1 capsular polysaccharide, a polymer of sialic acid, is an important virulence determinant of extraintestinal pathogenic Escherichia coli. The genes responsible for the synthesis and expression of the polysialic acid capsule of E. coli K1 are located on the 17-kb kps gene cluster, which is functionally divided into three regions. Central region 2 encodes proteins necessary for the synthesis, activation, and polymerization of sialic acid, while flanking regions 1 and 3 are involved in polymer transport to the cell surface. In this study, we identified two genes at the proximal end of region 2, neuD and neuB, which encode proteins with predicted sizes of 22.7 and 38.7 kDa, respectively. Several observations suggest that the neuB gene encodes sialic acid synthase. EV24, a neuB chromosomal mutant that expresses a capsule when provided exogenous sialic acid, could be complemented in trans by the cloned neuB gene. In addition, NeuB has significant sequence similarity to the product of the cpsB gene of Neisseria meningitidis group B, which is postulated to encode sialic acid synthase. We also present data indicating that neuD has an essential role in K1 polymer production. Cells harboring pSR426, which contains all of region 2 but lacks region 1 and 3 genes, produce an intracellular polymer. In contrast, no polymer accumulated in cells carrying a derivative of pSR426 lacking a functional neuD gene. Unlike strains with mutations in neuB, however, neuD mutants are not complemented by exogenous sialic acid, suggesting that NeuD is not involved in sialic acid synthesis. Additionally, cells harboring a mutation in neuD accumulated sialic acid and CMP-sialic acid. We also found no significant differences between the endogenous and exogenous sialyltransferase activities of a neuD mutant and the wild-type organism. NeuD shows significant similarity to a family of bacterial acetyltransferases, leading to the theory that NeuD is an acetyltransferase which may exert its influences through modification of other region 2 proteins.


Subject(s)
Acetyltransferases/genetics , Escherichia coli Proteins , Escherichia coli/genetics , Genes, Bacterial , Multigene Family , Oxo-Acid-Lyases/genetics , Sialic Acids/biosynthesis , Amino Acid Sequence , Bacterial Capsules/metabolism , Base Sequence , Escherichia coli/enzymology , Molecular Sequence Data , Mutation , Sequence Homology, Amino Acid
14.
Arch Pediatr Adolesc Med ; 148(5): 503-7, 1994 May.
Article in English | MEDLINE | ID: mdl-8180641

ABSTRACT

OBJECTIVE: To compare the safety and immunogenicity of a three-component acellular pertussis (DTaP) vaccine containing pertussis toxin (PT), filamentous hemagglutinin (FHA), and pertactin with whole-cell pertussis (DTwP) vaccine in 4- through 6-year-old children. PARTICIPANTS: One hundred seventy-two healthy 4- through 6-year-old children previously immunized with the DTwP vaccine at or near 2, 4, 6, and 18 months of age. INTERVENTIONS: Prevaccination serum samples were obtained on all study participants. One hundred twelve children received 0.5 mL of the DTaP vaccine intramuscularly. Fifty-three children received 0.5 mL of a commercially available DTwP vaccine intramuscularly. Approximately 30 days following vaccination, additional serum samples were obtained. MEASUREMENTS: Parents monitored adverse reactions for 7 days following immunization. Significantly fewer children in the DTaP group reported temperatures of greater than 38.1 degrees C and an area of redness of more than 10 mm and moderate-to-severe pain at the injection site. RESULTS: Antibody responses to PT, FHA, pertactin, and diphtheria and tetanus toxoids were measured by enzyme-linked immunosorbent assay. Among subjects who were seronegative prior to vaccination, response was defined as the detection of antibody levels following vaccination; among children with detectable antibody levels prior to vaccination, in terms of the rise in antibody titers. Data using a twofold and a fourfold rise in antibody titers as criteria to define response were evaluated. Children in the DTaP group had significantly greater increases in geometric mean titers of antibodies against PT, FHA, and pertactin. Over 90% of the DTaP group responded to PT, FHA, and pertactin according to the criteria of both the twofold and the fourfold rise in antibody titers. Significantly fewer of the DTwP group responded to PT, FHA, and pertactin with at least a fourfold rise in antibody titers. When analyzing subjects with at least a twofold increase in antibody titers, a statistically significant difference remained in regard to anti-FHA antibodies. All study subjects had protective antibody titers against diphtheria and tetanus toxoids following vaccination. The geometric mean titer of antibodies against tetanus was significantly greater in the DTwP group than in the DTaP group. CONCLUSION: The three-component DTaP vaccine administered as a booster immunization in 4-through 6-year-old children produced less fever and less redness and pain at the injection site than the DTwP vaccine and was as immunogenic as the DTaP vaccine.


Subject(s)
Adhesins, Bacterial , Antibodies, Bacterial/blood , Antigens, Bacterial/adverse effects , Antigens, Bacterial/immunology , Bacterial Outer Membrane Proteins/adverse effects , Bacterial Outer Membrane Proteins/immunology , Bordetella pertussis/immunology , Hemagglutinins/adverse effects , Hemagglutinins/immunology , Pertussis Vaccine/adverse effects , Pertussis Vaccine/immunology , Virulence Factors, Bordetella , Double-Blind Method , Drug Evaluation , Drug Monitoring , Humans , Infant , Pertussis Vaccine/classification , Vaccines, Combined
15.
Pediatr Ann ; 22(7): 401-5, 1993 Jul.
Article in English | MEDLINE | ID: mdl-8414693

ABSTRACT

While the incidence of HIV infection has leveled off in older homosexual men, infection in women, children, and adolescents is rising. Unless effective intervention measures are implemented, the number of pediatric patients with HIV and related illnesses will continue to increase. Interventions aimed at curtailing perinatal transmission potentially will have the greatest impact on decreasing the incidence of pediatric AIDS. Studies evaluating strategies aimed at this are currently underway. Educational initiatives targeting adolescents also may lower the number of pediatric patients with HIV infection. As treatments improve, the majority of HIV-infected children will survive for years and perhaps decades. The number of children with HIV infection in the upcoming decades will have a profound impact on our communities and our practice of pediatric medicine.


Subject(s)
HIV Infections/epidemiology , HIV-1 , Prenatal Exposure Delayed Effects , Adolescent , Child , Child, Preschool , Female , HIV Infections/congenital , HIV Infections/physiopathology , HIV Infections/therapy , HIV Infections/transmission , Humans , Infant , Pregnancy
SELECTION OF CITATIONS
SEARCH DETAIL
...